ES8605105A1 - Un conjugado de una molecula biologicamente activa - Google Patents

Un conjugado de una molecula biologicamente activa

Info

Publication number
ES8605105A1
ES8605105A1 ES536547A ES536547A ES8605105A1 ES 8605105 A1 ES8605105 A1 ES 8605105A1 ES 536547 A ES536547 A ES 536547A ES 536547 A ES536547 A ES 536547A ES 8605105 A1 ES8605105 A1 ES 8605105A1
Authority
ES
Spain
Prior art keywords
biologically active
target
metallothionein
trace
active molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES536547A
Other languages
English (en)
Spanish (es)
Other versions
ES536547A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EIDP Inc
Original Assignee
EI Du Pont de Nemours and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EI Du Pont de Nemours and Co filed Critical EI Du Pont de Nemours and Co
Publication of ES8605105A1 publication Critical patent/ES8605105A1/es
Publication of ES536547A0 publication Critical patent/ES536547A0/es
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6887—Antibody-chelate conjugates using chelates for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/804—Radioisotope, e.g. radioimmunoassay
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ES536547A 1983-10-06 1984-10-05 Un conjugado de una molecula biologicamente activa Expired ES8605105A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/539,733 US4732864A (en) 1983-10-06 1983-10-06 Trace-labeled conjugates of metallothionein and target-seeking biologically active molecules

Publications (2)

Publication Number Publication Date
ES8605105A1 true ES8605105A1 (es) 1986-02-16
ES536547A0 ES536547A0 (es) 1986-02-16

Family

ID=24152436

Family Applications (1)

Application Number Title Priority Date Filing Date
ES536547A Expired ES8605105A1 (es) 1983-10-06 1984-10-05 Un conjugado de una molecula biologicamente activa

Country Status (17)

Country Link
US (1) US4732864A (https=)
EP (1) EP0137457B1 (https=)
JP (2) JPS60166625A (https=)
KR (1) KR860001151B1 (https=)
AT (1) ATE32730T1 (https=)
AU (1) AU578428B2 (https=)
CA (1) CA1248090A (https=)
DE (1) DE3469536D1 (https=)
DK (1) DK162105C (https=)
ES (1) ES8605105A1 (https=)
FI (1) FI81263C (https=)
GR (1) GR80560B (https=)
IE (1) IE55709B1 (https=)
IL (1) IL73183A (https=)
NO (1) NO166267C (https=)
NZ (1) NZ209788A (https=)
ZA (1) ZA847797B (https=)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4707352A (en) * 1984-01-30 1987-11-17 Enzo Biochem, Inc. Method of radioactively labeling diagnostic and therapeutic agents containing a chelating group
US4880626A (en) * 1985-01-18 1989-11-14 Mcmichael John Immunotherapeutic methods and compositions for the treatment of diseases of viral origin, including acquired immune deficiency syndrome
NO167124C (no) * 1985-04-03 1991-10-09 Du Pont Merck Pharma Fremgangsmaate for fremstilling av et spormerket konjugat av metallthionein og biologisk aktivt molekyl.
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
JP2515357B2 (ja) * 1986-01-16 1996-07-10 ザ・ジェネラル・ホスピタル・コ−ポレ−ション 炎症の診断方法および治療方法
US5591581A (en) * 1986-04-30 1997-01-07 Igen, Inc. Electrochemiluminescent rhenium moieties and methods for their use
US6165729A (en) * 1986-04-30 2000-12-26 Hyperion Catalysis International, Inc. Electrochemiluminescent reaction utilizing amine-derived reductant
US6451225B1 (en) 1986-04-30 2002-09-17 Igen International, Inc. Electrochemiluminescent reaction utilizing amine-derived reductant
US4877599A (en) * 1986-11-10 1989-10-31 New England Deaconess Hospital Corporation Detection of vascular disease with labelled antibodies
US5672334A (en) * 1991-01-16 1997-09-30 Access Pharmaceuticals, Inc. Invivo agents comprising cationic metal chelators with acidic saccharides and glycosaminoglycans
WO1989004302A1 (en) * 1987-11-04 1989-05-18 Igen, Inc. Electrochemiluminescent rhenium moieties and methods
US5202451A (en) * 1988-02-17 1993-04-13 Neorx Corporation Anchimeric radiometal chelating compounds
USH735H (en) 1988-03-30 1990-02-06 The United States Of America As Represented By The United States Department Of Energy Lead-203 as a label for radioimaging
US5061641A (en) * 1988-04-01 1991-10-29 Immunomedics, Inc. Method for radiolabeling proteins
US5057301A (en) * 1988-04-06 1991-10-15 Neorx Corporation Modified cellular substrates used as linkers for increased cell retention of diagnostic and therapeutic agents
US5059541A (en) * 1988-04-29 1991-10-22 Neorx Corporation Minimal derivatization of proteins
US6702986B1 (en) 1988-04-29 2004-03-09 Igen International, Inc. Electrochemiluminescent reaction utilizing amine-derived reductant
US5972890A (en) * 1988-05-02 1999-10-26 New England Deaconess Hospital Corporation Synthetic peptides for arterial imaging
US5726153A (en) * 1988-05-02 1998-03-10 New England Deaconess Hospital Corporation Synthetic peptides for arterial imaging
US5218128A (en) * 1988-06-15 1993-06-08 Centocor, Inc. Bifunctional coupling agents and radionuclide labeled compositions prepared therefrom
WO1990006323A2 (en) * 1988-11-29 1990-06-14 Centocor, Inc. Chimeric proteins incorporating a metal binding protein
US5443816A (en) * 1990-08-08 1995-08-22 Rhomed Incorporated Peptide-metal ion pharmaceutical preparation and method
US5759515A (en) * 1989-08-09 1998-06-02 Rhomed Incorporated Polyvalent peptide pharmaceutical applications
US5078985A (en) * 1989-08-09 1992-01-07 Rhomed, Incorporated Radiolabeling antibodies and other proteins with technetium or rhenium by regulated reduction
US5985240A (en) * 1989-08-09 1999-11-16 Rhomed Incorporated Peptide radiopharmaceutical applications
DK0486622T3 (da) * 1989-08-09 1999-07-19 Rhomed Inc Direkte radiomærkning af antistoffer og andre proteiner med technetium eller rhenium
US5700444A (en) * 1992-02-20 1997-12-23 Rhomed Incorporated Chemotactic peptide pharmaceutical applications
US5747334A (en) * 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
US5498538A (en) * 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
EP0515516B1 (en) * 1990-02-15 2002-01-16 University of North Carolina Methods for identifying heterofunctional fusion proteins
US7238340B1 (en) 1991-11-27 2007-07-03 Cis Bio International Monoamine, diamide, thiol-containing metal chelating agents
US5645815A (en) 1991-02-08 1997-07-08 Diatide, Inc. Radiolabled compounds for thrombus imaging
US6019958A (en) * 1991-02-08 2000-02-01 Diatide, Inc. Technetium-99m labeled peptides for imaging inflammation
DE69230525T2 (de) * 1991-02-08 2000-06-21 Diatide, Inc. Technetium-99m markierte Polypeptide zur Bildformung
US6403771B1 (en) 1991-02-19 2002-06-11 Actinium Pharmaceuticals, Limited Method and means for site directed therapy
US6391590B1 (en) * 1991-10-21 2002-05-21 The Regents Of The University Of California Recombinant streptavidin-metallothionein chimeric protein having biological recognition specificity
US5738838A (en) * 1992-02-20 1998-04-14 Rhomed Incorporated IKVAV peptide radiopharmaceutical applications
US5556609A (en) * 1992-02-20 1996-09-17 Rhomed Incorporated YIGSR peptide radiopharmaceutical applications
US5643549A (en) * 1992-02-20 1997-07-01 Rhomed Incorporated Leukostimulatory agent for in vivo leukocyte tagging
US5326856A (en) * 1992-04-09 1994-07-05 Cytogen Corporation Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding
US5338686A (en) * 1992-04-29 1994-08-16 Hellerstein Marc K Method for measuring in vivo synthesis of biopolymers
CA2100709C (en) * 1992-07-27 2004-03-16 Maurits W. Geerlings Method and means for site directed therapy
US6203775B1 (en) * 1993-03-19 2001-03-20 The General Hospital Corporation Chelating polymers for labeling of proteins
IL109666A0 (en) * 1993-05-17 1994-08-26 Immunomedics Inc A targeting composition containing a biotin- or avidinprotein conjugate and methods for the use thereof
US6120768A (en) * 1993-05-17 2000-09-19 Immunomedics, Inc. Dota-biotin derivatives
ES2114209T3 (es) * 1993-07-19 1998-05-16 Resolution Pharm Inc Queladores de radionuclidos de tipo hidrazino que tienen una configuracion n3s.
WO1995004753A1 (en) * 1993-08-11 1995-02-16 University Of New Mexico Compositions of fusion proteins containing metallothionein and targeting-protein structural components
US5449761A (en) * 1993-09-28 1995-09-12 Cytogen Corporation Metal-binding targeted polypeptide constructs
US5942210A (en) * 1994-11-15 1999-08-24 Cytogen Corporation Methods for lyoprotecting a macromolecule using tricine
US5891418A (en) * 1995-06-07 1999-04-06 Rhomed Incorporated Peptide-metal ion pharmaceutical constructs and applications
US6331285B1 (en) 1996-06-05 2001-12-18 Palatin Technologies, Inc. Structurally determined cyclic metallo-constructs and applications
US7745142B2 (en) 1997-09-15 2010-06-29 Molecular Devices Corporation Molecular modification assays
US7632651B2 (en) 1997-09-15 2009-12-15 Mds Analytical Technologies (Us) Inc. Molecular modification assays
US7070921B2 (en) 2000-04-28 2006-07-04 Molecular Devices Corporation Molecular modification assays
US6248057B1 (en) 1998-07-28 2001-06-19 Innerdyne, Inc. Absorbable brachytherapy and chemotherapy delivery devices and methods
US6818611B1 (en) * 1998-10-13 2004-11-16 University Of Georgia Research Foundation, Inc. Stabilized bioactive peptides and methods of identification, synthesis and use
US20030190740A1 (en) 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
US7666609B1 (en) 1998-12-01 2010-02-23 Shanghai Cp Guojian Pharmaceutical Co. Ltd. Method and composition for diagnosis of melanocytic lesions
AU2591800A (en) * 1998-12-23 2000-07-31 Bert L. Vallee Synthetic and therapeutic methods for the alpha and beta domains of metallothionein
AU771248B2 (en) * 1999-01-22 2004-03-18 Martek Biosciences Corporation Simple method for labeled conjugate production
ES2198171B1 (es) * 2000-09-06 2005-04-16 Provital, S.A. Composicion cosmetica y/o farmaceutica conteniendo metalotioneina.
US7385025B2 (en) * 2000-12-19 2008-06-10 Palatin Technologies, Inc. Metallopeptide compounds
US20020117169A1 (en) 2001-02-27 2002-08-29 Kurz Daniel R. Cover and applicator for a portion of a mammalian body
EP1395226A4 (en) * 2001-06-11 2005-03-30 Univ Miami RADIOPHARMACEUTICAL COMPLEXES FOR TOLERATING TRANSPLANTATION
EP1507562B1 (en) * 2002-05-29 2010-03-24 Immunomedics, Inc. Compositions for radioimmunotherapy of brain
EP1554584B1 (en) * 2002-10-11 2008-05-07 Sentina Biotechnology Incorporated Methods for detection of breast cancer
CN1279056C (zh) * 2003-06-06 2006-10-11 马菁 肿瘤相关抗原sm5－1的特异性抗体及其应用
US20050232926A1 (en) * 2003-06-06 2005-10-20 Oncomax Acquisition Corp. Antibodies specific for cancer associated antigen SM5-1 and uses thereof
BRPI0414512B8 (pt) 2003-09-17 2021-05-25 Board Of Regentes The Univ Of Texas System composição para reproduzir imagens de um pâncreas e uso desta
CA2550900A1 (en) 2003-12-23 2005-07-07 Mount Sinai Hospital Methods for detecting markers associated with endometrial disease or phase
CN101921340A (zh) * 2004-03-31 2010-12-22 佳能株式会社 一种蛋白质
WO2006118615A2 (en) * 2004-12-16 2006-11-09 Brandeis University Clonable tag for purification and electron microscopy labeling
US8357720B2 (en) * 2005-03-23 2013-01-22 Florida Atlantic University Treatment or prevention of cancer and precancerous disorders
US8765808B2 (en) * 2005-03-23 2014-07-01 Chs Pharma, Inc. Treatment or prevention of cancer and precancerous disorders
EP1865972B1 (en) * 2005-03-23 2013-11-06 CHS Pharma, Inc. Treatment or prevention of cancer and precancerous disorders
WO2007130575A2 (en) * 2006-05-03 2007-11-15 Florida Atlantic University Protection against oxidative damage in cells
GB0621894D0 (en) * 2006-11-02 2006-12-13 Iti Scotland Ltd Magnetic recognition system
US20080269065A1 (en) * 2007-04-30 2008-10-30 Syntrix Biosystems, Inc. Conformationally Constrained Analytical Probes
WO2008141318A1 (en) * 2007-05-14 2008-11-20 Dr. Susan Love Research Foundation Device for determining risk of developing breast cancer and method thereof
CA2618163A1 (en) 2008-02-07 2009-08-07 K. W. Michael Siu Head and neck cancer biomarkers
GB0808086D0 (en) * 2008-05-02 2008-06-11 Iti Scotland Ltd Magnetic proteins for in vivo imaging
CN102088991A (zh) 2008-05-13 2011-06-08 堪萨斯大学 金属提取肽标签和相关方法
CN104710504B (zh) 2009-07-22 2019-09-13 锕医药股份有限公司 用于制备放射性免疫缀合物的方法
EP2486049A1 (en) 2009-10-06 2012-08-15 The Board Of Trustees Of The UniversityOf Illinois Human single-chain t cell receptors
EP2606165B1 (en) 2010-08-16 2016-10-12 Sinai Health System Markers of the male urogenital tract
US9187735B2 (en) 2012-06-01 2015-11-17 University Of Kansas Metal abstraction peptide with superoxide dismutase activity
EP3409297A1 (en) 2017-05-30 2018-12-05 AlfaRim Medial Holding B.V. The optimal 225actinium--213bismuth generator for alpha-particle radioimmunotherapy
WO2019057598A1 (en) 2017-09-20 2019-03-28 Alfarim Medical Holding B.V. OPTIMAL 225ACTINIUM - 213BISMUTH GENERATOR FOR ALPHA PARTICLE RADIO IMMUNOTHERAPY
KR20230173150A (ko) 2021-04-20 2023-12-26 테라파워, 엘엘씨 Ac-225 생성용 티타니아 기반 발생기

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56125317A (en) * 1980-03-08 1981-10-01 Nippon Mejifuijitsukusu Kk Stable radioactive diagnosticum with radioactive metallic mark
NO169947C (no) * 1981-10-27 1992-08-26 Hybritech Inc Fremgangsmaate for fremstilling av et monoklonalt antistoff til et tumorassosiert antigen
CA1222691A (en) * 1981-12-29 1987-06-09 Wilhelmus T. Goedemans Method of preparing radionuclide-labelled proteins, in particular antibodies or antibody fragments
US4472509A (en) * 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies

Also Published As

Publication number Publication date
US4732864A (en) 1988-03-22
IL73183A (en) 1991-09-16
DE3469536D1 (en) 1988-04-07
DK480284D0 (da) 1984-10-05
EP0137457B1 (en) 1988-03-02
NO844017L (no) 1985-04-09
NZ209788A (en) 1988-10-28
FI81263B (fi) 1990-06-29
FI843930L (fi) 1985-04-07
KR850002961A (ko) 1985-05-28
IE55709B1 (en) 1990-12-19
AU3362984A (en) 1985-04-18
NO166267B (no) 1991-03-18
EP0137457A2 (en) 1985-04-17
CA1248090A (en) 1989-01-03
AU578428B2 (en) 1988-10-27
JPH0470320B2 (https=) 1992-11-10
ATE32730T1 (de) 1988-03-15
IL73183A0 (en) 1985-01-31
EP0137457A3 (en) 1985-08-14
DK480284A (da) 1985-04-07
FI81263C (fi) 1990-10-10
NO166267C (no) 1991-06-26
IE842539L (en) 1985-04-06
ES536547A0 (es) 1986-02-16
JPH01294700A (ja) 1989-11-28
ZA847797B (en) 1986-05-28
DK162105C (da) 1992-02-17
DK162105B (da) 1991-09-16
GR80560B (en) 1985-02-06
FI843930A0 (fi) 1984-10-05
KR860001151B1 (ko) 1986-08-18
JPS60166625A (ja) 1985-08-29

Similar Documents

Publication Publication Date Title
ES8605105A1 (es) Un conjugado de una molecula biologicamente activa
FI902245A0 (fi) Nytt antikroppsdistributionssystem foer modifierare av biologisk respons.
GR1000454B (el) Νεο μονοκλωνικο αντισωμα κατα νεου αντιγονου που σχετιζεται με ανθρωπινους ογκους.
WO2000052054A3 (en) Antibodies for cancer therapy and diagnosis
ATE162403T1 (de) Modifizierte antikörper mit kontrollierter clearance-zeit
ES2052709T5 (es) Materiales inyectables para el aumento de tejidos blandos a partir de la placenta y su metodo de fabricacion.
DK124091D0 (da) Farmaceutisk genprodukt
KR900701321A (ko) 암 진단 및 치료용 면역접합체
ATE54417T1 (de) Radioaktiv markierte antikoerperstuecke.
ES8101384A1 (es) Procedimiento de preparacion de productos citotoxicos
FI88808C (fi) Menetelmä monoklonaalisten vasta-aineiden valmistamiseksi ihmisen ei-pienisoluisia keuhkosyöpäkasvaimia varten
FR2307623A1 (fr) Appareil destine a modifier la position angulaire d'un organe inciseur, ainsi que les positions relatives de couteaux fixes et mobiles portes par cet organe
RO82758A (ro) Procedeu de preparare a unor imunoglobulinei conjugate
SE8404283L (sv) Anvendning av ett specifikt tumorassocierat antigen, nemligen sialosyllaktotetraos, for diagnostiska och terapeutiska forfaranden vid cancersjukdomar
ES8800437A1 (es) Un procedimiento para la produccion de un conjugado marcado con un trazador de metalotioneina y una molecula biologicamente activa
NZ221065A (en) Conjugates of antibodies and toxins with sulphur-containing linking groups
ES8206855A1 (es) Un procedimiento para la preparacion de anticuerpos con especialidad frente a antigenos encontrados en los nucleos y nu-cleolos de las celulas humanas cancerosas.
ATE75487T1 (de) Langwirkende immunotoxine, die eine ribosominaktivierende, an ihren polysaccharidstellen modifizierte glycopeptidsubstanz umfassen.
IT7827685A0 (it) Forze di trazione in organi di dispositivo per l'introduzione di trazione costituiti da materiali fibrosi compositi allineati.
ATE58397T1 (de) Monoklonaler antikoerper geeignet zur spezifischen unterscheidung von humanen hepatokarzinomzellen.
ATE178493T1 (de) Stabilisierte antikörperfragmente
JPS6444856A (en) Anti-cancer antigen anti-serum
DE69012034D1 (de) Monoklonaler Antikörper gegen Exotoxin A von Pseudomonas aeruginosa.
ES8405155A1 (es) Procedimiento de inmunoanalisis para determinar etosuximida en una muestra de analisis.
ES243438U (es) Tubo perfeccionado.

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 19971001